YERVOY IPILPMUMAB 易普利姆玛伊匹单抗

Ipilimumab is an immune checkpoint inhibitor that enhances the ability of T cells to attack cancer cells by blocking the CTLA-4 protein. It is mainly used to treat malignant tumors such as advanced melanoma. It is the world’s first approved CTLA-4 inhibitor and needs to be used under the guidance of a doctor. It may cause immune-related side effects and needs to be closely monitored.

Indications and Mechanism of Action
Indications: Mainly used for the second-line treatment of unresectable or metastatic melanoma. It can also be used in combination with other drugs (such as PD-1 inhibitors) for some renal cancers, colorectal cancers, etc.
Mechanism of Action: CTLA-4 is the “brake” protein of the immune system. Ipilimumab inhibits CTLA-4, removes the restriction of T cell activity, and enhances anti-tumor immune response.
Common Side Effects and Treatment
Immune-related Adverse Reactions: Skin reactions (such as rash, itching); Gastrointestinal reactions (diarrhea, colitis); Endocrine abnormalities (hypothyroidism, hypophysitis); Liver toxicity (elevated transaminase).
‌Serious side effects‌:
It may cause pneumonia, myasthenia gravis or myocarditis, and the drug should be discontinued immediately and hormone treatment should be received.
Precautions for use ‌Pre-drug evaluation‌:
Liver function, thyroid function and baseline imaging results need to be checked.
‌Dosage and course of treatment‌:
Usually injected intravenously once every 3 weeks for a total of 4 courses. The specific plan is adjusted by the doctor according to the condition.
‌Contraindications‌:
Patients with allergies to drug ingredients, active autoimmune diseases or uncontrolled infections are prohibited.
‌Pregnant women and breastfeeding period‌:
It may affect fetal development. Strict contraception and avoid breastfeeding during medication.
Important tips ‌Ipilimumab is a prescription drug. It needs to be evaluated by an oncologist before use. Blood routine, liver and kidney function and other indicators need to be regularly reviewed during treatment.
If persistent diarrhea (>4 times/day), dyspnea or severe rash occurs, you need to seek medical attention immediately.
The efficacy of ipilimumab is related to the individual’s immune status. Some patients may benefit from long-term survival, but the risk of side effects needs to be weighed. During treatment, you need to keep communicating with your doctor to avoid adjusting the dose or stopping the medication on your own.